In the next section, we review the small molecule inhibitors that have been approved or are being investigated in combination with antiestrogens for the treatment of post-menopausal women with advanced HR positive, HER2 negative breast cancer in the first or later line settings, targeting both intrinsic and acquired resistance. Here, ERBB2 is linked to breast cancer.